Coherus BioSciences, Inc. (CHRS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1152495,
    "name": "Coherus BioSciences, Inc.",
    "stock_name": "Coherus BioSciences, Inc.",
    "full_name": "Coherus BioSciences, Inc.",
    "name_url": "stocks-analysis/coherus-biosciences-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.23",
    "chg": 0.07,
    "chgp": "6.03%",
    "dir": 1,
    "prev_price": "1.16",
    "mcapval": "159.23",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US19249H1032",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.66 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/coherus-biosciences-inc-1152495-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Coherus BioSciences Forms Golden Cross, Signaling Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/coherus-biosciences-forms-golden-cross-signaling-bullish-breakout-ahead-3552396",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/CoherusBioScien_goldencross_3552396.png",
        "date": "2025-09-22 18:01:05",
        "description": "Coherus BioSciences, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The company’s stock price rose notably, outperforming the S&P 500. Over the past year, Coherus has shown impressive gains, and current indicators suggest it may be gaining market traction."
      },
      {
        "title": "Is Coherus BioSciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coherus-biosciences-inc-technically-bullish-or-bearish-3547334",
        "imagepath": "",
        "date": "2025-09-20 19:53:02",
        "description": "As of 3 September 2025, the technical trend for Coherus BioSciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. However, the weekly RSI is bearish, and the daily moving averages indicate a mildly bearish stance. Overall, the Dow Theory and KST both reflect a mildly bullish outlook on the weekly and monthly charts. \n\nIn terms of performance, Coherus has significantly outperformed the S&P 500 over the past week and month, with returns of 15.04% and 42.99% compared to the S&P 500's 1.05% and 2.33%, respectively. However, over longer periods, such as 3 years and 5 years, the stock has underperformed the benchmark...."
      },
      {
        "title": "Is Coherus BioSciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-coherus-biosciences-inc-overvalued-or-undervalued-3543731",
        "imagepath": "",
        "date": "2025-09-20 18:27:11",
        "description": "As of 6 May 2021, the valuation grade for Coherus BioSciences, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative valuation metrics, including a Price to Book Value of -0.52 and an EV to EBITDA of -3.01. Additionally, the company's Return on Capital Employed (ROCE) stands at a concerning -350.73%, further supporting the notion of overvaluation.\n\nIn comparison to peers, Coherus BioSciences has a significantly lower EV to EBITDA ratio of 0.2081 compared to SIGA Technologies, Inc., which boasts a ratio of 4.3137 and is rated attractive. Other risky peers like Nurix Therapeutics, Inc. show an EV to EBITDA of -1.2267, but still, Coherus's metrics are alarming. Despite a strong 1-month stock return of 42.99% compared to the S&P 500's 2.33%, the long-term performance is troubling, with a 5-year return of -92.31% versus the S&..."
      }
    ],
    "total": 8,
    "sid": "1152495",
    "stock_news_url": "https://www.marketsmojo.com/news/coherus-biosciences-inc-1152495"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Coherus BioSciences Forms Golden Cross, Signaling Bullish Breakout Ahead

2025-09-22 18:01:05

Coherus BioSciences, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The company’s stock price rose notably, outperforming the S&P 500. Over the past year, Coherus has shown impressive gains, and current indicators suggest it may be gaining market traction.

Is Coherus BioSciences, Inc. technically bullish or bearish?

2025-09-20 19:53:02

As of 3 September 2025, the technical trend for Coherus BioSciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. However, the weekly RSI is bearish, and the daily moving averages indicate a mildly bearish stance. Overall, the Dow Theory and KST both reflect a mildly bullish outlook on the weekly and monthly charts. In terms of performance, Coherus has significantly outperformed the S&P 500 over the past week and month, with returns of 15.04% and 42.99% compared to the S&P 500's 1.05% and 2.33%, respectively. However, over longer periods, such as 3 years and 5 years, the stock has underperformed the benchmark....

Is Coherus BioSciences, Inc. overvalued or undervalued?

2025-09-20 18:27:11

As of 6 May 2021, the valuation grade for Coherus BioSciences, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative valuation metrics, including a Price to Book Value of -0.52 and an EV to EBITDA of -3.01. Additionally, the company's Return on Capital Employed (ROCE) stands at a concerning -350.73%, further supporting the notion of overvaluation. In comparison to peers, Coherus BioSciences has a significantly lower EV to EBITDA ratio of 0.2081 compared to SIGA Technologies, Inc., which boasts a ratio of 4.3137 and is rated attractive. Other risky peers like Nurix Therapeutics, Inc. show an EV to EBITDA of -1.2267, but still, Coherus's metrics are alarming. Despite a strong 1-month stock return of 42.99% compared to the S&P 500's 2.33%, the long-term performance is troubling, with a 5-year return of -92.31% versus the S&...

View All News